Exclusive technology and marketing collaboration for sublingual delivery

25 Feb 2019

WuXi STA will have exclusive access to BioLingus's novel platform to stabilize and deliver sublingually drug targets including small molecules, peptides and proteins, that are currently administered to patients via injection.

STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, and BioLingus, a Swiss biotech company, have formed an exclusive technology and marketing collaboration for sublingual delivery.

Exclusive technology and marketing collaboration for sublingual delivery

Under the terms of the collaboration, WuXi STA will have exclusive access to BioLingus technology for sublingual and buccal delivery in the CDMO sector. BioLingus has developed a novel platform – with patents secured in major countries around the world – to stabilize and deliver sublingually drug targets including small molecules, peptides and proteins, that are currently administered to patients via injection.

The collaboration will help further integrate the advantages of WuXi STA drug product services and expedite the development of BioLingus’ pipeline and usage of sublingual delivery technology.

In 2017, WuXi STA merged with WuXi AppTec’s Pharmaceutical Development Services unit, realizing a seamless integration of the entire chemistry, manufacturing and controls (CMC) supply chain. Over the past year, two new commercial drug product facilities – in Shanghai and Wuxi city, Jiangsu province – have come into operation, enabling WuXi STA to support solid dosage drug development from preclinical to commercial, with several phase III and commercial drug product projects underway. The newly introduced sublingual delivery technology will further deepen the scale of solid dosage drug capabilities in WuXi STA, providing customers with more flexible, diverse and advanced solutions.

“We entered into this exclusive collaboration with WuXi STA for this technology in the CDMO sector for a number of reasons. Principally, WuXi STA is one of the world leaders in this field, with an integrated CMC platform from pre-clinical development to commercialization. Furthermore, this partnership will help us develop our own client base on a global scale faster and more broadly than we could do on our own.” said Yves Decadt, CEO of BioLingus.

Dr Minzhang Chen, CEO of WuXi STA, added: “We are very pleased to partner with BioLingus and to offer their award-winning sublingual delivery technology to global new drug developers via WuXi STA’s integrated CMC platform. This collaboration will, therefore, offer more economical, convenient and effective delivery solutions for patients globally.”

Read More

Related news

Zenith Technologies sees 400% China growth in latest Asia success

Zenith Technologies sees 400% China growth in latest Asia success

22 May 2019

Company plans to double its operations in the country over the next 3 years and expand its work with local companies as well as continuing to support global multinationals.

Read more 
Online training for pharmaceutical and nutraceutical professionals

Online training for pharmaceutical and nutraceutical professionals

21 May 2019

Modules include a variety of subjects from an ’Introduction to tablet tooling’ and ‘Tooling maintenance’, to ‘Troubleshooting production problems’ and ‘Improving productivity’.

Read more 
FDA approves TraceLink DSCSA pilot submission for network solutions

FDA approves TraceLink DSCSA pilot submission for network solutions

20 May 2019

Delivering 2023 traceability by leveraging blockchain and digital recalls across a supply network.

Read more 
UK and US customers set to benefit from Wasdell Group acquisition

UK and US customers set to benefit from Wasdell Group acquisition

17 May 2019

Increased manufacturing and packaging capacity and service in the UK allows company to better service growing client base in the US who require a fully outsourced supply chain for their products within Europe.

Read more 
Improving gut health with human milk oligosaccharides

Improving gut health with human milk oligosaccharides

17 May 2019

2’-FL a very promising agent for digestive health across various age groups beyond infancy.

Read more 
Expert forecasts huge growth in Middle East manufacturing

Expert forecasts huge growth in Middle East manufacturing

16 May 2019

UAE consumers and insurance companies are willing to pay for highest quality drug products.

Read more 
Colorcon's breakthrough for direct compression

Colorcon's breakthrough for direct compression

15 May 2019

New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.

Read more 
Legacy plans for lyophilisation boom

Legacy plans for lyophilisation boom

14 May 2019

The increase in biologics is driving the growth in demand for lyophilization in vials.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Catalent achieves global ISO accreditation

Catalent achieves global ISO accreditation

12 May 2019

Company is one of the first CDMOs to receive award.

Read more